Verve Therapeutics Statistics
Total Valuation
Amedisys has a market cap or net worth of $3.32 billion. The enterprise value is $3.43 billion.
| Market Cap | 3.32B |
| Enterprise Value | 3.43B |
Important Dates
The last earnings date was Tuesday, July 29, 2025, after market close.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Amedisys has 32.89 million shares outstanding. The number of shares has increased by 1.10% in one year.
| Current Share Class | 32.89M |
| Shares Outstanding | 32.89M |
| Shares Change (YoY) | +1.10% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 1.92% |
| Owned by Institutions (%) | 92.13% |
| Float | 32.24M |
Valuation Ratios
The trailing PE ratio is 39.16 and the forward PE ratio is 20.23. Amedisys's PEG ratio is 1.36.
| PE Ratio | 39.16 |
| Forward PE | 20.23 |
| PS Ratio | 1.38 |
| Forward PS | 1.29 |
| PB Ratio | 2.69 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.12 |
| P/OCF Ratio | 13.86 |
| PEG Ratio | 1.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.56, with an EV/FCF ratio of 14.61.
| EV / Earnings | 40.09 |
| EV / Sales | 1.43 |
| EV / EBITDA | 13.56 |
| EV / EBIT | 15.19 |
| EV / FCF | 14.61 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.35.
| Current Ratio | 1.36 |
| Quick Ratio | 1.30 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | 1.54 |
| Debt / FCF | 1.92 |
| Interest Coverage | 8.19 |
Financial Efficiency
Return on equity (ROE) is 6.67% and return on invested capital (ROIC) is 8.36%.
| Return on Equity (ROE) | 6.67% |
| Return on Assets (ROA) | 6.52% |
| Return on Invested Capital (ROIC) | 8.36% |
| Return on Capital Employed (ROCE) | 13.09% |
| Revenue Per Employee | $126,440 |
| Profits Per Employee | $4,507 |
| Employee Count | 19,000 |
| Asset Turnover | 1.11 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Amedisys has paid $67.42 million in taxes.
| Income Tax | 67.42M |
| Effective Tax Rate | 45.16% |
Stock Price Statistics
The stock price has increased by +3.22% in the last 52 weeks. The beta is 0.90, so Amedisys's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | +3.22% |
| 50-Day Moving Average | 97.22 |
| 200-Day Moving Average | 93.33 |
| Relative Strength Index (RSI) | 74.49 |
| Average Volume (20 Days) | 660,134 |
Short Selling Information
The latest short interest is 2.24 million, so 6.82% of the outstanding shares have been sold short.
| Short Interest | 2.24M |
| Short Previous Month | 2.16M |
| Short % of Shares Out | 6.82% |
| Short % of Float | 6.95% |
| Short Ratio (days to cover) | 4.66 |
Income Statement
In the last 12 months, Amedisys had revenue of $2.40 billion and earned $85.63 million in profits. Earnings per share was $2.58.
| Revenue | 2.40B |
| Gross Profit | 1.04B |
| Operating Income | 226.03M |
| Pretax Income | 143.78M |
| Net Income | 85.63M |
| EBITDA | 253.06M |
| EBIT | 226.03M |
| Earnings Per Share (EPS) | $2.58 |
Balance Sheet
The company has $337.30 million in cash and $450.51 million in debt, giving a net cash position of -$113.20 million or -$3.44 per share.
| Cash & Cash Equivalents | 337.30M |
| Total Debt | 450.51M |
| Net Cash | -113.20M |
| Net Cash Per Share | -$3.44 |
| Equity (Book Value) | 1.27B |
| Book Value Per Share | 37.48 |
| Working Capital | 173.84M |
Cash Flow
In the last 12 months, operating cash flow was $239.43 million and capital expenditures -$4.41 million, giving a free cash flow of $235.02 million.
| Operating Cash Flow | 239.43M |
| Capital Expenditures | -4.41M |
| Free Cash Flow | 235.02M |
| FCF Per Share | $7.15 |
Margins
Gross margin is 43.19%, with operating and profit margins of 9.41% and 3.56%.
| Gross Margin | 43.19% |
| Operating Margin | 9.41% |
| Pretax Margin | 6.21% |
| Profit Margin | 3.56% |
| EBITDA Margin | 10.53% |
| EBIT Margin | 9.41% |
| FCF Margin | 9.78% |
Dividends & Yields
Amedisys does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.10% |
| Shareholder Yield | -1.10% |
| Earnings Yield | 2.58% |
| FCF Yield | 7.08% |
Analyst Forecast
The average price target for Amedisys is $100.67, which is -0.27% lower than the current price. The consensus rating is "Hold".
| Price Target | $100.67 |
| Price Target Difference | -0.27% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 5, 2006. It was a forward split with a ratio of 1.33333:1.
| Last Split Date | Dec 5, 2006 |
| Split Type | Forward |
| Split Ratio | 1.33333:1 |
Scores
Amedisys has an Altman Z-Score of 4.04 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.04 |
| Piotroski F-Score | 6 |